Statins are less effective in common daily practice among patients with hypercholesterolemia: the REALITY-PHARMO study

被引:32
作者
Goettsch, WG
Yin, DD
Alemao, E
Klungel, OH
Stalenhoef, AF
Herings, RMC
机构
[1] PHARMO Inst, NL-3508 AE Utrecht, Netherlands
[2] Univ Nijmegen, Med Ctr, Dept Gen Internal Med, Nijmegen, Netherlands
[3] Univ Utrecht, Utrecht Inst Pharmaceut Sci, Utrecht, Netherlands
[4] Merck & Co Inc, Whitehouse Stn, NJ USA
关键词
cholesterol; total levels; daily practice; goal attainment; hypercholesterolemia; statins; potency;
D O I
10.1185/030079904125004114
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: To study the use and effectiveness of lipid-lowering drugs with respect to lowering of cholesterol levels in routine daily practice. Methods: 20 392 patients for whom lipid levels records were available between January 1991 and December 2001 were included in this retrospective population based cohort study. From this group of patients 1899 patients started treatment during the study period and had at least one baseline cholesterol measurement during the six months prior to the initiation of lipid lowering drugs and at least one cholesterol measurement after initiation. A patient was defined to be 'at goal' if the patient had a total cholesterol less than 5.0 mmol/L. Results: Our results indicate that only 30.2% of all treated patients achieved goal in the first year of treatment. After the introduction of new guidelines in 1998, recommending more aggressive treatment, the goal attainment percentage rose from 22.4% of those patients treated before 1998 to 42.3% for those in whom treatment was initiated after 1998. Conclusion: The percentage of patients achieving guideline recommended goal is low in real-life even in patients treated with high dose statins.
引用
收藏
页码:1025 / 1033
页数:9
相关论文
共 40 条
[1]  
*3 REP NAT CHOL ED, 2001, NIH PUBL
[2]   Use and monitoring of "statin" lipid-lowering drugs compared with guidelines [J].
Abookire, SA ;
Karson, AS ;
Fiskio, J ;
Bates, DW .
ARCHIVES OF INTERNAL MEDICINE, 2001, 161 (01) :53-58
[3]  
[Anonymous], HUISARTS WET
[4]   Persistence of use of lipid-lowering medications - A cross-national study [J].
Avorn, J ;
Monette, J ;
Lacour, A ;
Bohn, RL ;
Monane, M ;
Mogun, H ;
LeLorier, J .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1998, 279 (18) :1458-1462
[5]   Risk for myopathy with statin therapy in high-risk patients [J].
Ballantyne, CM ;
Corsini, A ;
Davidson, MH ;
Holdaas, H ;
Jacobson, TA ;
Leitersdorf, E ;
März, W ;
Reckless, JPD ;
Stein, EA .
ARCHIVES OF INTERNAL MEDICINE, 2003, 163 (05) :553-564
[6]   Age and gender bias in statin trials [J].
Bandyopadhyay, S ;
Bayer, AJ ;
O'Mahony, MS .
QJM-AN INTERNATIONAL JOURNAL OF MEDICINE, 2001, 94 (03) :127-132
[7]   Systematic review on the risk and benefit of different cholesterol-lowering interventions [J].
Bucher, HC ;
Griffith, LE ;
Guyatt, GH .
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 1999, 19 (02) :187-195
[8]  
Catalan V S, 2000, Value Health, V3, P417, DOI 10.1046/j.1524-4733.2000.36006.x
[9]  
*CBO, 1998, BEH PREV COR HARTZ D
[10]  
Clearfield Michael B, 2002, Expert Opin Pharmacother, V3, P469, DOI 10.1517/14656566.3.5.469